Skip to main content

Table 1 Patients and provider characteristics

From: Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study

 

Breast cancer

Carboplatin-treated lung cancer

Cisplatin-treated lung cancer

 

All

Older 5-HT3RAs

Palonosetron

P

All

Older 5-HT3RAs

Palonosetron

P

All

Older 5-HT3RAs

Palonosetron

P

N

3,606

1,742

1,864

 

4,497

2,691

1,806

 

1,154

764

390

 

Age mean (SD)

53.7 (9.8)

53.7 (9.7)

53.7 (10.0)

NS

64.9 (10.2)

64.77 (10.2)

65.03 (10.3)

NS

60.5 (9.8)

60.1 (9.8)

61.3 (9.8)

0.0476

CCI mean (SD)

0.5 (1.0)

0.5 (1.1)

0.5 (1.0)

NS

6.8 (3.2)

6.87 (3.2)

6.71 (3.2)

NS

6.5 (3.3)

6.6 (3.3)

6.3 (3.2)

NS

Female, N (%)

-

-

-

-

2,080 (46.3)

1,258 (46.8)

822 (45.5)

NS

459 (39.8)

329 (43.1)

130 (33.3)

0.0014

Year of 5-HT 3 RA initiated

   

<0.0001

   

<0.0001

   

NS

2005

1,428 (39.6)

753 (43.3)

675 (36.2)

 

1,562 (34.7)

990 (36.8)

572 (31.7)

 

348 (30.2)

247 (32.3)

101 (25.9)

 

2006

1,537 (42.6)

720 (41.3)

817 (43.8)

 

1,480 (32.9)

857 (31.9)

623 (34.5)

 

394 (34.1)

263 (34.4)

131 (33.6)

 

2007

520 (14.4)

223 (12.8)

297 (15.9)

 

1,140 (25.4)

687 (25.5)

453 (25.1)

 

315 (27.3)

194 (25.4)

121 (31.0)

 

2008

121 (3.4)

46 (2.6)

75 (4.0)

 

315 (7.0)

157 (5.8)

158 (8.8)

 

97 (8.4)

60 (7.9)

37 (9.5)

 
  1. P: P value; CCI: Charlson Comorbidity Index; 5-HT3 RAs: 5-hydroxytryptamine receptor antagonists.